newlink genetics | unlea... Marktanteilsanalyse für April 2026

newlink genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. newlink genetics' ido pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. indoximod is being evaluated in combination with treatment regimens including anti-pd-1/pd-l1 agents, cancer vaccines, and chemotherapy across multiple indications such as melanoma, pancreatic cancer and other malignancies.